menu
    • menu
    [{"orgOrder":0,"company":"Treeway","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TW001","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase II","graph3":"Treeway","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treeway \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Treeway \/ Undisclosed"},{"orgOrder":0,"company":"Treeway","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Treeway","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Treeway \/ Specialised Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Treeway \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Treeway","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Treeway","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Treeway \/ Treeway","highestDevelopmentStatusID":"10","companyTruncated":"Treeway \/ Treeway"}]

    Find Clinical Drug Pipeline Developments & Deals by Treeway

    Menu

    Treeway

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Treeway

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Treeway

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Specialised Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Treeway Licensing Deal with Specialised Therapeutics

                            Details : Under the licensing agreement, ST will be responsible for all marketing, regulatory and distribution activities of TW001, a unique oral formulation of edaravone which works by reducing the oxidative damage associated with neuron death in ALS, in Australi...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 28, 2023

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Specialised Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Treeway

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Treeway

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TW001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ASURE: Alzheimer Study Using oRal Edaravone

                            Details : TW001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2022

                            Lead Product(s) : TW001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Treeway

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Treeway

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Ferrer Internacional

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ferrer Signs License Agreement To Develop An Oral Formulation Treatment For Patients With ALS

                            Details : FNP122 is an oral formulation of edaravone, a compound that prevents oxidative stress on a cellular level. Therefore, reducing oxidative stress can delay the progression of ALS.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 20, 2021

                            Lead Product(s) : Edaravone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Ferrer Internacional

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth